ONCOLYTIC VIRUS FOR
LIVER CANCER
PHOCUS was a patient selection failure. The mechanism wasn't disproven. Current HCC programmes enrolling earlier-line patients and combining with checkpoint inhibitors are the direct operational response.
What PHOCUS Actually Showed
Phase II TRAVERSE showed tumour necrosis, AFP reduction, and OS signals in sorafenib-naive patients. Phase III PHOCUS enrolled sorafenib-pretreated patients β a different population with more prior treatment and different immune microenvironment. Post-hoc analyses confirmed the Phase II signal population was not the Phase III enrolled population.
βIn oncology, Phase II signals in population A don't automatically translate to Phase III success in population B. PHOCUS didn't show Pexa-Vec doesn't work β it showed patient selection determined the outcome.β
Post-PHOCUS HCC Programmes
Current programmes explicitly address the PHOCUS patient selection error.
Vaccinia + Checkpoint Inhibitor Combinations
Pexa-Vec + nivolumab and similar combinations in Phase I/II. Explicitly enrolling earlier-line, sorafenib-naive patients.
VG161 (Multi-Payload HSV)
Engineered HSV carrying IL-12, IL-15, and anti-PD-1 antibody fragments β all expressed at the tumour site during replication. Phase I/II in multiple solid tumours including HCC.
Portal Vein / Hepatic Artery Delivery
Multifocal HCC makes single-lesion injection insufficient. Research exploring distribution through portal vein or hepatic artery to cover the liver simultaneously.
Frequently Asked Questions
HCC Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Interested in Oncolytic Virus for Liver Cancer?
Upload your medical reports for a free evaluation. Our team will identify the most relevant oncolytic virus programmes and clinical trials for your specific diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.